Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $222.5 million.

  • Mirum Pharmaceuticals' Cash & Equivalents rose 26.48% to $282.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.0 million, marking a year-over-year increase of 26.48%. This contributed to the annual value of $222.5 million for FY2024, which is 22.29% down from last year.
  • According to the latest figures from FY2024, Mirum Pharmaceuticals' Cash & Equivalents is $222.5 million, which was down 22.29% from $286.3 million recorded in FY2023.
  • Mirum Pharmaceuticals' Cash & Equivalents' 5-year high stood at $286.3 million during FY2023, with a 5-year trough of $128.0 million in FY2022.
  • For the 3-year period, Mirum Pharmaceuticals' Cash & Equivalents averaged around $212.3 million, with its median value being $222.5 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 123.69% in 2023, then fell by 22.29% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash & Equivalents (Yearly) stood at $142.1 million in 2020, then dropped by 7.56% to $131.3 million in 2021, then declined by 2.54% to $128.0 million in 2022, then surged by 123.69% to $286.3 million in 2023, then dropped by 22.29% to $222.5 million in 2024.